A small study suggests that in select patients with long-lasting disease stabilization, elective discontinuation of CDK4/6 inhibitors is feasible. Read More ›

A large retrospective cohort population-based study demonstrated a disproportionate elevation of breast cancer–specific and all-cause mortality among African American women. Read More ›

For the treatment of patients with HR-positive/HER2-negative metastatic breast cancer, targeting CDK4/6 represents a novel, effective, and safe therapeutic approach in combination with hormone therapy. Read More ›

Study results suggest the potential of clinical development of estrogen receptor, CDK4/6, and AKT co-targeting strategies after progression on a CDK4/6 inhibitor and endocrine therapy combination, and in tumors showing high phospho-AKT levels. Read More ›

Medicaid expansion under the Affordable Care Act was associated with significant increases in breast reconstruction surgery among non-Hispanic black women and women with lower income and education levels, according to results of a study presented during the American Society of Breast Surgeons 22nd Annual Meeting. Read More ›

The addition of the tyrosine kinase inhibitor tucatinib (Tukysa) to trastuzumab (Herceptin) and capecitabine continued to improve overall survival (OS) and progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer, according to updated results from the pivotal HER2CLIMB trial. Read More ›

Evidence from studies indicates that common genetic and epigenetic features of male and female breast cancer are not shared, but further studies are warranted. Read More ›

Breast cancer survivors should be closely monitored and offered appropriate evidence-based treatment for fatigue, cognitive dysfunction, and sexual problems. Read More ›

Page 7 of 29

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: